COVINGTON

Boston Life Sciences Symposium

TUESDAY, MAY 14, 2024 | MANDARIN ORIENTAL, BOSTON

Time Slot	Session	Description
9:30 a.m. – 10:00 a.m.	*Registration and Breakfast*	
10:00 a.m. – 10:05 a.m.	*Opening Remarks* **Michael Labson**, Partner, Covington	
10:05 a.m. – 10:55 a.m.	**Plenary Session One:** *Life Sciences Industry Work in China: An Evolving National Security Landscape* ▪ **Michael Labson**, Moderator, Partner, Covington ▪ **John Balzano,** Partner, Covington ▪ **Jennifer Plitsch,** Partner, Covington ▪ **Julia Post,** Of Counsel, Covington ▪ **Stephen Rademaker,** Senior Of Counsel, Covington	Concerns about U.S. national security risks arising from certain types of foreign access to U.S. personal information have led to several federal legislative and executive measures and proposals in recent months. This panel will discuss the contours and potential implications of the BIOSECURE Act, possible designations of certain Chinese companies to various sanctions lists, and President Biden's "Executive Order on Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern" and the accompanying Advance Notice of Proposed Rulemaking. These proposals present potentially important considerations for life sciences companies to navigate when doing business with or in China.
10:55 a.m. – 11:05 a.m.	*Morning Break*	
11:05 a.m. – 11:55 a.m.	**Plenary Session Two:** Corporate Deal Trends ▪ **Lauren Rakitin**, Moderator, Partner, Covington ▪ **Ron Cooper**, former CEO, Albireo Pharma, Inc. ▪ **John Hurvitz**, Partner, Covington ▪ **Rajinder Khunkhun**, Head, Neuroscience Business Development, Takeda ▪ **Sean Pitt**, Senior Managing Director, Biopharma, Leerink Partners	This panel will cover learning from recent corporate transactions in the biopharma space, including licensing, collaborations, financings, and M&A. Topics to be addressed will include deal structuring, notable therapeutic areas and modalities (including cell and gene therapy, and ADCs), recommendations for execution, and trends to watch in the coming year.
11:55 a.m. – 12:25 p.m.	*Buffet Luncheon*	
12:25 p.m. - 1:10 p.m.	**Luncheon Program** Keynote speaker, **Dr. John Maraganore** (former founding CEO at Alnylam Pharmaceuticals) A Conversation with **Megan Gates**, Partner, Covington	This program will include a discussion by Dr. John Maraganore, who will share his journey building Alnylam Pharmaceuticals into a global, commercial-stage biopharmaceutical company developing novel therapeutics based on RNAi, followed by a conversation with Covington Capital Markets and Securities Practice Group Partner, Megan Gates.

COVINGTON

Boston Life Sciences Symposium

TUESDAY, MAY 14, 2024 | MANDARIN ORIENTAL, BOSTON

Time Slot	Session	Description
1:10 p.m. – 1:20 p.m.	*Afternoon Break*	
1:20 p.m. – 1:40 p.m.	**CovTalk Session:** *Administrative Law in a Post-Chevron World* ▪ **Jerry Masoudi**, Partner, Covington	The Supreme Court is considering cases that could end *Chevron* deference, which shields certain agency actions if the agency has adopted a "reasonable" or "permissible" interpretation of an ambiguous statute. These cases could change significantly the balance of power between the judiciary and executive agencies. Former FDA Chief Counsel and Covington partner Jerry Masoudi will discuss the pending Supreme Court cases, possible outcomes, and what it all means for companies in the life sciences sector.
1:40 p.m. – 2:00 p.m.	**CovTalk Session:** *In for a Penny, In for a Pound: How Drug Pricing Reforms and Investigations are Reshaping the Industry* ▪ **Rujul Desai**, Partner, Covington	This session featuring Covington Health Care Partner, Rujul Desai, will provide a holistic and forward looking view of how drug pricing and supply chain reforms and investigations at the federal and state level are leading to a new paradigm in how life science companies will approach key commercialization activities from early product regulatory strategies and collaborations, to new product launches, supply chain relationships, and engagement with government oversight bodies. Specific developments discussed will include IRA, PDABs, 340B litigation, ERISA fiduciary litigation, DOJ, FTC and Congressional investigations, as well as supply chain, value framework and patient access developments.
2:00 p.m. – 2:05 p.m.	*Mini-Break*	
2:05 p.m. – 2:55 p.m.	**Plenary Session Three:** *AI Governance for Life Sciences Companies* ▪ **David Wildman,** Moderator, Partner, Covington ▪ **Elizabeth Canter**, Partner, Covington ▪ **Katherine Fick**, Associate General Counsel, Privacy & AI, IBM ▪ **Betsy McSheffrey**, Vice President, Head Counsel, Global Data, Digital & Technology, Takeda	The life sciences sector, much like other industries, is swiftly adopting AI technologies to enhance automation, increase efficiency, and unearth new opportunities across various functions, from backend operations to fundamental research and throughout the product lifecycle. In this session, we'll delve into emerging models and best practices for implementing enterprise-wide AI governance. Topics will include how pharma and medical device companies are structuring governance functions and addressing regulatory, ethical, and strategic challenges to navigate the landscape of AI-driven innovation responsibly and effectively.
2:55 p.m. – 3:00 p.m.	*Closing Remarks* **Michael Labson**, Partner, Covington	
3:00 p.m. – 4:00 p.m.	*Afternoon Reception*	